With nearly 50 years of experience and expertise in the pharmaceutical and biopharmaceutical industry, we are focused on unique products, solutions and platforms for diagnostics, therapeutic and health care across Asia and emerging markets.
Innogene Kalbiotech has been successful in obtaining registrations and marketing authorisation in many ASEAN countries as well as other nations for oncology drug(s) and for biosimilars.
Our partners can leverage our expertise and experience to better understand the market needs and regulatory requirements to develop their products for launch in the Asian market. In Singapore and Taiwan, we have worked closely with the authorities to benefit patients while finalising Phase 3 clinical trial reports for key oncology indications.
We are able to in-license both early and late stage development of molecules and technologies. We have a proven track record of advancing such products along the clinical development and regulatory pathway to commercialization.
Our partnership opportunities extend to in-licensing, joint ventures, co-development, product or company acquisition, out-licensing and commercialization.
Click here to see a list of our trusted long standing partnerships.